Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple therapy with semaglutide vs iGlarLixi for newly diagnosed type 2 diabetes
ChiCTR2400089972Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide, insulin glargine + lixisenatide, metformin and empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: HbA1c. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400089972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089972.